Company intelligence / Profile preview

SAFC

St. Louis, Missouri, USAsafc.com ↗

Ownership: Private
Employees: ~1000
Development stage: Commercial

Overview

SAFC was a leading global provider of high-quality specialty chemicals and biologics with expertise in GMP custom manufacturing of APIs and drug products. It offered comprehensive support from preclinical development to large-scale commercialization across small molecules and biologics. Its capabilities included highly potent API production, antibody-drug conjugates manufacture, viral vectors/vaccines production, cell culture media/reagents supply chain management. SAFC did not have its own clinical pipeline but enabled client programs through contract services.

Modalities: Small moleculeMonoclonal antibodyAntibody-drug conjugateViral vector therapyRNA therapyBiologicVaccineCell culture media and reagents
Industry: Contract Manufacturing Organization

Partnerships

Cherokee Pharmaceuticalsnumerous pharma/biopharma clients globally

Beyond the preview

Go deeper on SAFC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAFC.

Explore the full profile